Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Clicks: 515
ID: 110503
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 85 articles by views in inflammatory bowel diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Compared with placebo, 35%-40% more patients receiving a full induction course of vedolizumab had sustained clinical remission after 52 weeks of therapy. This result was observed irrespective of TNF antagonist treatment history. Clinical remission at week 14 may therefore be a predictor for sustaine …
Reference Key
bg2019inflammatorysustained Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Schreiber S;Wolf DC;Axler JL;Kaviya A;James A;Curtis RI;Geransar P;Stallmach A;Ehehalt R;Bokemeyer B;Khalid JM;O'Byrne S;;
Journal inflammatory bowel diseases
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/30365009/##supplemental-data
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine prognosis research support non-u.s. gov't adult female male Remission Induction Antibodies Monoclonal follow-up studies pmid:30365009 PMC6499937 doi:10.1093/ibd/izy323 Brian G Feagan Stefan Schreiber Sharon O'Byrne Humanized / therapeutic use* Colitis Ulcerative / drug therapy* Gastrointestinal Agents / therapeutic use* Induction Chemotherapy* Severity of Illness Index*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.